Esophageal neoplasia-associated cell surface markers

Esophageal neoplasia-associated cell surface markers refer to a heterogeneous collection of proteins and glycoproteins expressed on the outer membrane of cells during the development of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) [PubMed: 31435456]. These markers, which include the Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Claudin 18.2, play pivotal roles in driving oncogenic processes such as cell proliferation, survival, and metastasis [National Cancer Institute]. In the context of clinical oncology, these surface molecules are utilized as diagnostic tools and therapeutic targets for monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies [PubMed: 33808140]. For instance, Trastuzumab targets HER2-positive esophageal cancers, while newer agents like Zolbetuximab target Claudin 18.2 [ClinicalTrials.gov]. Because this term describes a broad category of distinct molecular entities rather than a single receptor or enzyme, it is typically used to define the surface proteome landscape of esophageal tumors for biomarker discovery [UniProt]. Consequently, while the individual components are valid therapeutic targets, the collective designation serves as a framework for multi-target diagnostic and therapeutic strategies.

Other names

Esophageal cancer surface antigensESCC surface markersEAC surface markersEsophageal tumor-associated antigensEsophageal cancer surface proteome

Inhibition of oncogenic signaling pathways, induction of antibody-dependent cellular cytotoxicity (ADCC), and targeted delivery of cytotoxic payloads to malignant cells.